EGFR and central nervous system cancer: Interestingly, another recent study carried out on 87 H3-IDHWT high-grade pediatric gliomas, excluding from the analysis tumors with PXA- or LGG-like patterns, allowed the subdivision of these tumors into three subgroups; to some extent comparable with those of the previous study: a MYCN group enriched in MYCN amplification and associated with poor outcomes; a RTK1 group, enriched in PDGFRA amplification and associated with an intermediate prognosis; a RTK2 group, enriched in EGFR amplification and associated with a longer survival time [72].